Royalty Revenue Acceleration
Royalty revenue was $43.0M in Q1 2026, up 56% year-over-year, driven primarily by Filspari, Ohtuvayre and Qarziba.
Ligand Pharma
· LGND
May 7th, 2026
Summary
- Earnings Call Date:
- 2026-05-07
- Change Since:
- +35.46%
- Next Earnings Date:
- 2026-08-11
Earnings Call Sentiment
PositiveThe earnings call was broadly positive: the company reported strong underlying operating momentum (royalty revenue +56% YoY, total revenue +14% YoY, adjusted EPS +23% YoY), meaningful near-term and long-term growth catalysts (Filspari approval and Palvella Phase III success), a transformative announced acquisition (XOMA) expected to be immediately accretive and to materially scale the portfolio, and a strong liquidity position. Key risks discussed include GAAP volatility from equity fair-value movements, lumpy Captisol/contract revenue and timing dependence on partner execution, and remaining uncertainty until the XOMA transaction closes and its tax attributes are fully quantified. Overall, the positives — including multiple high-value clinical and commercial catalysts and a materially enlarged, diversified portfolio — outweigh the highlighted near-term financial and timing uncertainties.
Company Guidance
Ligand reiterated 2026 guidance assuming the XOMA Royalty deal closes in Q3: total revenue $270–$310 million, royalty revenue $225–$250 million and adjusted EPS $8.50–$9.50, with XOMA expected to add ~$0.50 of adjusted EPS in 2026 and ~$1.50 in 2027; the company also expects combined operating cash flow of approximately $300 million (reflecting acquired tax attributes) and plans to deploy $150–$250 million annually into new royalty opportunities. Management noted Q1 results of $52 million total revenue (up 14% YoY), $43 million royalty revenue (up 56% YoY), adjusted EPS $1.63 (up 23% YoY) and GAAP diluted loss per share of $0.67, ending the quarter with ~$780 million cash and investments plus $200 million undrawn revolver (~$1 billion available). Additional near-term guides included Captisol contract revenue visibility to meet a $35–$40 million range and the potential for milestones and additional earnings from XOMA’s portfolio post-close.
Total Revenue and Adjusted EPS Growth
Total revenue was $52.0M, up 14% year-over-year. Adjusted diluted EPS was $1.63, an increase of 23% versus the prior year period.
XOMA Royalty Acquisition — Scale and Near-Term Accretion
Announced acquisition of XOMA Royalty (expected to close in Q3 2026) will add >120 commercial/clinical/preclinical assets, seven marketed products, nearly double Phase II/III assets, and is expected to be immediately accretive: +$0.50 adjusted EPS in 2026 and +$1.50 in 2027; management also expects significant operational synergies and tax benefits.
Major Clinical and Regulatory Catalysts (Palvella and Filspari)
Palvella's QTORIN rapamycin reported positive Phase III SELVA results with a +2.13 improvement on the mLM-IGA primary endpoint (vs. Palvella's guide of +1 and upside of +1.5); Palvella plans NDA submission in H2 2026. Travere's Filspari received full FDA approval for FSGS, expanding label and creating a larger commercial opportunity.
Large Peak Opportunity Signals for Key Assets
Management cited estimated commercial peak opportunities: Travere's Filspari ~ $3.0B peak sales across IgAN and FSGS (implying ~$270M annual royalty to Ligand if achieved); QTORIN rapamycin peak U.S. sales estimated $1.0B–$3.0B across initial indications (implying $100M–$300M peak royalty to Ligand).
Improved Operating Efficiency and Scale
Since pivoting to a royalty aggregation model, Ligand reduced operating footprint (from ~200 to ~40 employees historically), lowered operating expenses from ~$90M to ~$40M, expanded deal team to 18, and grew commercial assets from 7 to 15 while closing 18 deals in the last 3 years.
Strong Liquidity Position
Approximately $780M cash and investments at quarter end plus $200M undrawn revolver capacity — nearly $1.0B of available capital to fund XOMA close and continued deal activity.
Multi-year Guidance and Cash Flow outlook
2026 guidance (assuming XOMA close in Q3): total revenue $270M–$310M, royalty revenue $225M–$250M, adjusted EPS $8.50–$9.50. Management expects combined operating cash flow of ~ $300M in 2027 and plans $150M–$250M annual deployment into new royalty opportunities.
Operator
Hello, everyone. Thank you for joining us, and welcome to Ligand's First Quarter 2026 Earnings Call. [Operator Instructions] I will now hand the conference over to Melanie Herman, head of [Technical Difficulty]. Please go ahead.
Melanie Herman
Good morning, everyone, and welcome to Ligand's First Quarter 2026 Earnings Call. With me on the call today are CEO, Todd Davis; Chief Financial Officer, Octavio Espinoza, Vice President of Portfolio Strategy and Investments, Lauren Hay; and Vice President of Investments and Business Development, Michael Vigilante. During the call today, we will review the financial results released earlier today and provide commentary on our partner portfolio and business development activities, followed by a question-and-answer session. Before we get started, I would like to point out that we will be discussing non-GAAP results, which exclude certain items such as stock-based compensation, amortization of intangible assets, amortization or impairment of financial assets and gains or losses from derivative assets, amongst others. I encourage you to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP measures, which can be found in today's release available on our website. We believe these adjusted measures provide valuable insight into our core operating performance, both historically and moving forward. Our earnings release and a link to today's webcast can be found in the Investor Relations section of our website at ligand.com. This call is being recorded, and the audio portion will be archived in the Investors section of o...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free